2026 be­gins with con­sid­er­able op­ti­mism about the clin­i­cal re­search fund­ing en­vi­ron­ment. Phar­ma­ceu­ti­cal com­pa­nies are ac­tive­ly ac­quir­ing biotech in­no­va­tors, and in a marked con­trast to the sit­u­a­tion at this time last year, promis­ing op­por­tu­ni­ties are emerg­ing for both biotechs and in­vestors alike.

Here are five key in­sights to help biotech lead­ers at­tract ven­ture cap­i­tal fund­ing in to­day's com­pet­i­tive land­scape. These in­sights are drawn from a re­cent we­bi­nar and episode from our Clin­i­cal Tri­al­blaz­er's pod­cast se­ries fea­tur­ing Dr. Gee­ta Ve­muri, Founder and Man­ag­ing Part­ner at Agent Cap­i­tal.

Most im­por­tant­ly, you must ar­tic­u­late a com­pelling prod­uct and com­pa­ny vi­sion that res­onates with in­vestors. At ear­ly fund­ing stages, the fi­nal com­mer­cial prod­uct of­ten re­mains years away, re­quir­ing ex­ten­sive re­search and de­vel­op­ment be­fore reach­ing mar­ket vi­a­bil­i­ty. This re­al­i­ty means that your vi­sion is crit­i­cal. In­vestors need to see and un­der­stand your pro­ject­ed endgame: a sci­en­tif­i­cal­ly sound and eco­nom­i­cal­ly vi­able so­lu­tion for ad­dress­ing an un­met need.

Your as­set pro­jec­tions should demon­strate:

• A clear de­vel­op­ment path­way through clin­i­cal phas­es
• Deep un­der­stand­ing of the un­der­ly­ing sci­ence
• Com­pre­hen­sive mar­ket knowl­edge
• Re­al­is­tic time­lines for achiev­ing mile­stones

CEOs who can en­vi­sion this tra­jec­to­ry and com­mu­ni­cate it with both clar­i­ty and pas­sion will build the in­vestor trust es­sen­tial for se­cur­ing fund­ing com­mit­ments.

Tri­als fail for nu­mer­ous rea­sons, in­clud­ing in­suf­fi­cient fund­ing, but many pit­falls are avoid­able with the right ear­ly strate­gies. Suc­cess hinges on risk mit­i­ga­tion through metic­u­lous plan­ning, ro­bust study de­sign, and skilled over­sight and man­age­ment. The in­ter­nal staff, ven­dors, and con­tract re­search or­ga­ni­za­tions (CROs) you part­ner with must deeply un­der­stand your sci­ence, bring proven ex­pe­ri­ence, and be ful­ly aligned with your prod­uct vi­sion.

In­vestors scru­ti­nize not just your sci­ence, but your ex­e­cu­tion ca­pa­bil­i­ties. They nat­u­ral­ly fa­vor en­tre­pre­neurs with proven track records, mak­ing cred­i­bil­i­ty a steep­er hur­dle for first‑time founders. With­out pri­or wins, demon­strat­ing that you've sur­round­ed your­self with ex­pe­ri­enced, tal­ent­ed part­ners who share your pas­sion be­comes es­sen­tial. In­no­v­a­tive sci­ence alone can­not car­ry an as­set to mar­ket; it re­quires the right team and rig­or­ous plan­ning to en­sure prop­er ex­e­cu­tion at every stage.

All en­tre­pre­neur­ship in­volves ex­ter­nal vari­ables be­yond one’s con­trol. The un­fore­seen fac­tors you can­not plan for that ei­ther work in your fa­vor or against you. The re­al­i­ty is that even com­pa­nies with a his­to­ry of suc­cess can do every­thing right and still have dif­fi­cul­ty rais­ing cap­i­tal.

Clin­i­cal de­vel­op­ment is unique­ly vul­ner­a­ble to forces be­yond any team’s con­trol—from reg­u­la­to­ry shifts and eco­nom­ic swings to com­peti­tor break­throughs and chang­ing mar­ket dy­nam­ics. Be­cause ad­vanc­ing an as­set from ear­ly re­search to ap­proval takes years, pro­grams face pro­longed ex­po­sure to these pres­sures. What looks like a strong in­vest­ment cli­mate to­day can shift dra­mat­i­cal­ly by the time piv­otal tri­al da­ta emerges.

The key is to con­trol what you can con­trol (tri­al de­sign, ex­e­cu­tion qual­i­ty, site se­lec­tion, etc.) while re­main­ing ag­ile enough to adapt to ex­ter­nal changes you can't.

Bio­phar­ma­ceu­ti­cal de­vel­op­ment is a team ef­fort and the strength of your in­ter­nal and ex­ter­nal part­ner­ships di­rect­ly im­pacts your abil­i­ty to se­cure cap­i­tal. Your net­work opens doors; your board pro­vides cred­i­bil­i­ty and con­nec­tions; and your ex­ec­u­tive team's co­he­sion gives in­vestors con­fi­dence that their cap­i­tal is in ca­pa­ble hands.

These re­la­tion­ships take time to build, but they can be as crit­i­cal as the sci­ence it­self. In an in­dus­try where the ma­jor­i­ty of drug can­di­dates fail, in­vestors seek every sig­nal that your com­pa­ny will suc­ceed, and the qual­i­ty of your part­ner­ships and team­work can re­in­force that. Com­pa­nies that mas­ter the art of col­lab­o­ra­tion are the ones that se­cure the fund­ing need­ed to turn sci­en­tif­ic promise in­to re­al­i­ty.

Max­i­miz­ing the val­ue and in­sights from every dol­lar spent is im­per­a­tive, di­rect­ly de­ter­min­ing your run­way to demon­strate your drug’s po­ten­tial. Every dol­lar counts—and in­vestors no­tice as it sig­ni­fies man­age­ment com­pe­tence.

Smart cap­i­tal al­lo­ca­tion now de­mands a glob­al mind­set. Mul­ti-re­gion­al tri­als can ac­cel­er­ate en­roll­ment and low­er costs com­pared to US/FDA-cen­tric ap­proach­es. Ge­o­graph­ic di­ver­si­fi­ca­tion stretch­es bud­gets and re­duces risk, po­si­tion­ing com­pa­nies for sus­tain­able suc­cess across mul­ti­ple mar­kets.

Biotech drug de­vel­op­ment de­mands more than great sci­ence, it re­quires strate­gic vi­sion, strong lead­er­ship, op­er­a­tional dis­ci­pline, and the right part­ners. With 2026 bring­ing re­newed op­ti­mism through ris­ing M&A ac­tiv­i­ty, mar­ket sta­bi­liza­tion, and op­por­tu­ni­ties from patent ex­pi­ra­tions, well‑po­si­tioned com­pa­nies have a win­dow to se­cure fund­ing.

To stand out, think like an in­vestor: pair your sci­en­tif­ic ex­cel­lence with a clear, cred­i­ble de­vel­op­ment strat­e­gy. And to nav­i­gate the most crit­i­cal ear­ly stages, re­ly on an ex­pe­ri­enced CRO part­ner who can turn a promis­ing idea in­to an in­vestable path for­ward.

Ready to dive deep­er? Hear Dr. Gee­ta Ve­muri and fel­low pod­cast guests dis­cuss cap­i­tal ef­fi­cien­cy strate­gies in our lat­est we­bi­nar.

Ex­plore more from our Clin­i­cal Tri­ablaz­ers pod­cast se­ries where break­through sci­ence meets the sto­ries be­hind it.

At Parex­el Biotech, our un­ri­valed reg­u­la­to­ry and sci­en­tif­ic ex­per­tise, cou­pled with ear­ly-phase tri­al ca­pa­bil­i­ties, ac­cel­er­ate the path from con­cept to clin­i­cal proof. We help val­i­date the sci­ence, op­ti­mize fund­ing op­por­tu­ni­ties, and pre­pare in­no­va­tions for piv­otal pa­tient tri­als, faster. Learn more about how our biotech ex­perts can help you: Biotech Clin­i­cal Tri­al So­lu­tions | Parex­el